National Institute on Drug Abuse; Notice of Closed Meetings, 52480 [2024-13709]
Download as PDF
<![CDATA[
52480
Federal Register / Vol. 89, No. 121 / Monday, June 24, 2024 / Notices
umbrella collection would enable HRSA
to collect information from individual
and site applicants and enable HRSA to
make selection determinations for onetime awards in a timely manner.
Information collections under this
umbrella generic collection would be
applications for funding (solely
providing applicants with an
opportunity to demonstrate their
capabilities in accordance with HRSA’s
statement of work or selection criteria
and other related information) and
forms required for monitoring funding
recipients. Following the award, the
awardee may also be required to provide
progress reports or additional
documents.
Likely Respondents: Each fast-track
ICR under this generic umbrella ICR
will specify the manner that
respondents will be enlisted.
Respondents will vary by the specific
program and are determined by each
program’s eligibility, to include but are
not limited to the following: health
providers and other paraprofessionals,
health facilities, accredited health
professions schools or programs, state
and local governments, and other
eligible entities.
Respondents will be recruited by
means of information listed on HRSA’s
website, or advertisements in public
venues. The privacy of any potential or
actual respondents will be preserved to
the extent requested by participants and
as permitted by law.
Once applicants are selected and
awards are made, these awardees will be
respondents for monitoring collections
such as progress reports.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating, and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information.
HRSA intends to use this generic
umbrella ICR for applications with a
low burden and monitoring awardees.
To estimate the burden for this
collection, HRSA estimated how much
time it would take for a respondent to
complete a two-page application with
typical fields used in current collections
that may fall under this generic
umbrella ICR. HRSA then calculated the
average burden estimate from these ICRs
for the purpose of the estimate for this
ICR. To estimate the burden for
monitoring funding recipients, HRSA
estimated how much time it would take
for funding recipients to complete the
average two-page form used for program
monitoring. The total burden hours over
a 3-year period estimated for this ICR
are summarized in the table below.
TOTAL ESTIMATED BURDEN HOURS OVER 3 YEARS
Estimated
number of
respondents
Instrument name
Estimated
total
responses
Average
burden per
response
(in hours)
Total burden
hours
Program Applications ...........................................................
Program Monitoring .............................................................
5,000
2,500
1.5
1.0
7,500
2,500
1.75
2.00
13,125
5,000
Total ..............................................................................
7,500
........................
10,000
........................
18,125
Maria G. Button,
Director, Executive Secretariat.
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
[FR Doc. 2024–13713 Filed 6–21–24; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
lotter on DSK11XQN23PROD with NOTICES1
Average
number of
responses per
respondent
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
VerDate Sep<11>2014
18:55 Jun 21, 2024
Jkt 262001
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; GMP
Synthesis of Bulk Drug Testing.
Date: July 18, 2024.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Meysam Yazdankhah,
Ph.D., Scientific Review Officer, Scientific
Review Branch, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 402–
6965 meysam.yazdankhah@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA–
L Conflict SEP.
Date: July 23, 2024.
Time: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
PO 00000
Frm 00048
Fmt 4703
Sfmt 9990
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sudhirkumar U.
Yanpallewar, M.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 443–4577, sudhirkumar.yanpallewar@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: June 17, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–13709 Filed 6–21–24; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\24JNN1.SGM
24JNN1
]]>Agencies
[Federal Register Volume 89, Number 121 (Monday, June 24, 2024)]
[Notices]
[Page 52480]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-13709]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; GMP Synthesis of Bulk Drug Testing.
Date: July 18, 2024.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Meysam Yazdankhah, Ph.D., Scientific Review
Officer, Scientific Review Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892,
(301) 402-6965 [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA-L Conflict SEP.
Date: July 23, 2024.
Time: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sudhirkumar U. Yanpallewar, M.D., Scientific
Review Officer, Scientific Review Branch, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD
20892, (301) 443-4577, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: June 17, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-13709 Filed 6-21-24; 8:45 am]
BILLING CODE 4140-01-P
